ARBUTUS BIOPHARMA CORPORATION — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$14M
R&D
$25M
D&A
$363K
Operating Income
$-38M
EBITDA
$-38M
Interest Expense
$97K
Interest Income
$4M
Other Income/Expense
$46M
Pretax Income
$12M
Tax Provision
$0
Net Income
$-34M
Operating Margin
-271.0%
Net Margin
-237.9%
Effective Tax Rate
0.0%
Deferred Tax Assets
—
Deferred Tax Liabilities
—
DTA Valuation Allowance
$181M
Tax Credit Carryforwards
$9M
NOL Carryforwards
$111M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
25.0%
Operating Lease Cost
$300K
Revenue YoY Variation
128.2%
Income YoY Variation
50.0%